Federal Cannabis Reclassification in the U.S.: What Changed in April 2026 and What It Means for LatAm

On April 23, 2026, the United States Department of Justice (DOJ) formalized the reclassification of certain cannabis products from Schedule I to Schedule III of the Controlled Substances Act. The measure was announced by the DOJ's Office of Public Affairs and published in the Federal Register under document 2026-08176. It is worth specifying from the outset the actual scope of the decision: the reclassification does not legalize cannabis at the federal level, does not decriminalize consumption, and does not bring recreational market operators into the federal system. What it does is reorganize the status of a narrow category of products and, in doing so, modify the tax, banking, and research conditions surrounding part of the industry.

For Latin American actors —export-oriented producers, patient associations, funds, and investors— the relevant question is not whether the United States "legalized," but which subset of the market became authorized to operate under different rules and what signals that decision sends to the international regulatory order.

What Exactly Was Reclassified

The order covers two narrowly defined universes. The first is cannabis pharmaceutical products approved by the Food and Drug Administration (FDA). The second is products regulated under a state medical license, that is, those circulating within the medical cannabis programs authorized by each state. Deliberately left outside the change are adult-use or recreational market products, which remain in Schedule I for federal purposes.

This narrowing explains why the technical reading differs from general media coverage. Schedule III groups substances with an accepted medical use and a relatively lower potential for abuse; placing FDA-approved medical products and state-licensed regulated products there recognizes, in administrative terms, a category of therapeutic use. It does not constitute a general authorization for commerce. Analyses by firms such as Holland & Knight and Hogan Lovells have emphasized that the practical effect concentrates on three narrow fronts, not on an opening of the market.

The Three Doors That Open

Section 280E of the Internal Revenue Code. Section 280E prevents businesses that traffic in Schedule I or II substances from deducting ordinary operating expenses, which translates into effective tax burdens far higher than those of any other industry. By moving medical products to Schedule III, that restriction no longer applies to operators that qualify. The change materially improves the margins of companies operating within the reclassified segment, without affecting the situation of those that remain in Schedule I.

Banking access. The Schedule I status has been the central argument behind the reluctance of federally regulated banking to serve the industry. The reclassification reduces, though does not entirely eliminate, the regulatory friction for financial institutions to provide services to the medical segment. The expected effect is a gradual normalization of access to accounts, credit, and payment services for operators that qualify.

Scientific research. Schedule I imposes severe procedural barriers to cannabis research. The move to Schedule III simplifies the requirements for clinical and preclinical studies, which can accelerate the generation of evidence and, eventually, broaden the universe of FDA-approved pharmaceutical products. This point is of particular interest for LatAm: a more robust evidence base produced in the United States tends to permeate the region's regulatory frameworks.

The Procedural Hooks: Order, Treaties, and Hearing

Three elements of the process merit monitoring by Latin American operators and investors.

First, the order was signed by the Acting Attorney General, Todd Blanche, as announced by the DOJ's Office of Public Affairs. The route used and the signing authority are relevant because they condition the legal soundness of the act and its exposure to challenge.

Second, the framework contemplates an international treaty compliance pathway. The United States is a party to the 1961 Single Convention on Narcotic Drugs (Convención Única de 1961 sobre Estupefacientes), which obliges States to maintain controls over cannabis. The existence of a pathway designed to reconcile the reclassification with those obligations is significant for the region: it offers a precedent on how a State party can move a substance between domestic schedules without entering into formal conflict with the international drug control regime, a debate that also runs through several Latin American countries.

Third, the process provides for an administrative hearing scheduled for June 29, 2026. Until that proceeding concludes, part of the practical effects could remain subject to additional regulatory development. Operators with an interest in the U.S. market should treat the timeline following that date as the horizon on which the described conditions will consolidate —or be adjusted.

The Two-Tier Status

The most structurally relevant outcome is the consolidation of a two-tier status within the United States. On one side, operators in the medical segment —FDA-approved products and products regulated by state medical license— are placed in Schedule III, with relief under Section 280E, better banking access, and lower research barriers. On the other, adult-use market operators remain in Schedule I, under the previous tax and banking regime.

This bifurcation redefines the relative appeal of each segment. For a Latin American exporter or investor, the direct implication is that the channel with greater regulatory predictability toward the U.S. market is the pharmaceutical and regulated medical one, not the recreational one. A product aspiring to integrate into U.S. supply chains under the new framework will have to align with pharmaceutical quality standards and with the requirements of state medical programs, not with the logic of the consumer market.

What It Means for Latin America

The consequences for the region operate on two planes. On the regulatory plane, the decision reinforces the international trend of treating medical cannabis as a differentiated pharmaceutical category, subject to evidence and sanitary control. This is consistent with the direction taken by frameworks such as those of Brazil, Colombia, and Argentina, and it gives Latin American regulators an additional argument to sustain demanding quality schemes.

On the commercial and investment plane, the tax and banking improvement of the U.S. medical segment increases the capacity of those operators to source supply, scale, and eventually import. The opportunity for LatAm is conditioned on traceability and good practice standards: only producers capable of documenting origin, quality, and regulatory compliance will be able to insert themselves sustainably into supply chains that now operate with lower financial friction but with regulatory requirements intact.

Analytical caution is warranted. Until the administrative hearing of June 29, 2026 concludes and the subsequent regulatory development settles, several effects should be read as a probable trend rather than as consolidated certainty.

For Latin American companies evaluating exposure to the U.S. market or that need to structure an export operation under these new parameters, CannaTech provides regulatory advisory and market development services aimed at translating international regulatory changes into concrete operational decisions.

Sources

• DOJ — Office of Public Affairs
• Federal Register — document 2026-08176
• Holland & Knight
• Hogan Lovells